Last 28 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.63 | 1.00 | 0.75 | 0.64 | 0.61 | 0.39 | 0.35 | 0.44 | 0.39 | 0.39 | 0.41 | 0.71 | 1.27 | 1.32 | 0.95 | 1.62 | 2.08 | 2.34 | 3.24 | 3.39 | 4.15 |
| — | +155.2% | +112.6% | +43.8% | +57.9% | +0.8% | -14.0% | -37.4% | -69.4% | -70.4% | -56.6% | -56.3% | -39.0% | -43.8% | -70.8% | -52.3% | -50.0% | -48.6% | -23.3% | -47.9% | +13.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.4% | -22.7% | -18.7% | -16.0% | -16.1% | -14.1% | -10.4% | -12.3% | -9.3% | -0.6% | -7.0% | -6.8% | -7.3% | -7.8% | -8.0% | -7.6% | -6.8% | -6.1% | -6.1% | -5.8% | -4.5% |
| — | -60.8% | -80.5% | -29.9% | -72.6% | -2382.7% | -48.9% | -80.8% | -27.6% | +92.7% | +13.3% | +10.8% | -7.9% | -27.9% | -30.8% | -31.6% | -49.6% | -62.2% | -87.2% | -101.8% | -17.0% | |
| ROA | -50.5% | -20.2% | -16.9% | -14.4% | -14.7% | -13.1% | -9.6% | -11.1% | -8.3% | -0.5% | -6.2% | -6.1% | -6.6% | -7.0% | -7.3% | -7.0% | -6.2% | -5.6% | -5.7% | -5.4% | -4.3% |
| — | -54.4% | -75.7% | -29.9% | -76.1% | -2464.4% | -54.3% | -80.6% | -26.1% | +92.7% | +14.4% | +11.9% | -6.2% | -25.0% | -28.0% | -28.2% | -45.2% | -55.1% | -76.9% | -92.3% | -13.4% | |
| ROIC | -63.4% | -26.1% | -24.4% | -18.8% | -18.5% | -16.5% | -13.1% | -12.6% | -9.6% | -8.5% | -7.2% | -7.1% | -8.2% | -11.5% | -12.8% | -9.7% | -7.7% | -6.9% | -8.3% | -9.0% | -7.1% |
| — | -57.9% | -86.1% | -49.1% | -91.7% | -95.2% | -82.3% | -78.1% | -17.9% | +26.0% | +43.6% | +27.2% | -5.7% | -66.8% | -53.2% | -8.0% | -8.8% | -5.4% | +34.2% | — | +99.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 |
| — | -58.2% | -51.8% | +18.4% | -88.5% | -88.0% | -88.7% | -88.5% | +25.4% | +1.7% | +4.6% | +3.6% | +11.4% | +31.0% | +45.6% | +56.6% | +39.0% | +36.7% | +1347.3% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.09 | 7.70 | 11.14 | 10.09 | 10.76 | 12.52 | 16.75 | 12.22 | 13.98 | 19.22 | 16.79 | 14.78 | 19.16 | 16.63 | 22.03 | 22.80 | 22.75 | 24.76 | 24.65 | 24.66 | 36.62 |
| — | -38.5% | -33.5% | -17.4% | -23.0% | -34.9% | -0.2% | -17.3% | -27.0% | +15.5% | -23.8% | -35.2% | -15.8% | -32.8% | -10.6% | -7.5% | -37.9% | -42.5% | -57.3% | -56.7% | -46.3% | |
| Quick Ratio | 10.09 | 7.70 | 11.14 | 10.09 | 10.76 | 12.52 | 16.75 | 12.22 | 13.98 | 19.22 | 16.79 | 14.78 | 19.16 | 16.63 | 22.03 | 22.80 | 22.75 | 24.76 | 24.65 | 24.66 | 36.62 |
| — | -38.5% | -33.5% | -17.4% | -23.0% | -34.9% | -0.2% | -17.3% | -27.0% | +15.5% | -23.8% | -35.2% | -15.8% | -32.8% | -10.6% | -7.5% | -37.9% | -42.5% | -57.3% | -56.7% | -46.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PMVP stock.
PMV Pharmaceuticals, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PMV Pharmaceuticals, Inc.'s business trajectory between earnings reports.